These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 14754454)
1. 3D QSAR models of interactions between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones. Manetti F; Maccari L; Corelli F; Botta M Curr Top Med Chem; 2004; 4(2):203-17. PubMed ID: 14754454 [TBL] [Abstract][Full Text] [Related]
2. 3D QSAR studies of the interaction between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones. Manetti F; Forli S; Maccari L; Corelli F; Botta M Farmaco; 2003 May; 58(5):357-61. PubMed ID: 12729829 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilones. Forli S; Manetti F; Altmann KH; Botta M ChemMedChem; 2010 Jan; 5(1):35-40. PubMed ID: 19904799 [No Abstract] [Full Text] [Related]
4. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720 [TBL] [Abstract][Full Text] [Related]
5. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Fojo T; Menefee M Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560 [TBL] [Abstract][Full Text] [Related]
8. 3D QSAR studies for the beta-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs): a pseudoreceptor model for taxanes based on the experimental structure of tubulin. Maccari L; Manetti F; Corelli F; Botta M Farmaco; 2003 Sep; 58(9):659-68. PubMed ID: 13679158 [TBL] [Abstract][Full Text] [Related]
11. Epothilone B and its analogs - a new family of anticancer agents. Altmann KH Mini Rev Med Chem; 2003 Mar; 3(2):149-58. PubMed ID: 12570848 [TBL] [Abstract][Full Text] [Related]
12. Relationship between the structures of taxane derivatives and their microtubule polymerization activity. Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785 [TBL] [Abstract][Full Text] [Related]
13. Novel drugs targeting microtubules: the role of epothilones. Ferrandina G; Mariani M; Andreoli M; Shahabi S; Scambia G; Ferlini C Curr Pharm Des; 2012; 18(19):2793-803. PubMed ID: 22390763 [TBL] [Abstract][Full Text] [Related]
14. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Canta A; Chiorazzi A; Cavaletti G Curr Med Chem; 2009; 16(11):1315-24. PubMed ID: 19355888 [TBL] [Abstract][Full Text] [Related]
15. The biology and medicinal chemistry of epothilones. Wartmann M; Altmann KH Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):123-48. PubMed ID: 12678754 [TBL] [Abstract][Full Text] [Related]
16. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973 [TBL] [Abstract][Full Text] [Related]
18. Site occupancy calibration of taxane pharmacology in live cells and tissues. Pineda JJ; Miller MA; Song Y; Kuhn H; Mikula H; Tallapragada N; Weissleder R; Mitchison TJ Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11406-E11414. PubMed ID: 30429313 [TBL] [Abstract][Full Text] [Related]
19. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro. Cai P; Lu P; Sharom FJ; Fang WS Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826 [TBL] [Abstract][Full Text] [Related]
20. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]